1. Market Research
  2. > Biotechnology
  3. > Biopharmaceutical Market Trends
  4. > Physician Views – Are physicians getting the biosimilar education they need?

Biosimilars remain one of the pharmaceutical industry's hot topics. Branded biologics account for 7 of the 10 best selling drugs globally and significant legislative momentum was provided in 2013 when the European Medicines Agency (EMA) approved its first biosimilar antibody products (versions of the anti-TNF Remicade). There may be less regulatory momentum in the US market but further insight from the FDA – including its views on interchangeability – is expected to emerge over the next 12 months.

With approval of the first biosimilar antibodies, however, there has been a steady shift in focus from the development/regulatory space to the commercial landscape. Many questions are being asked; how will biosimilars compete on price?, what sales and marketing infrastructure will be necessary to support uptake? And, increasingly, are physicians ready for biosimilars and is the industry doing enough to educate who is arguably the key stakeholder in this market?

As physician familiarity with the biosimilar concept inevitably increases, this exposure will raise further pertinent questions for the practising community; interchangeability (i.e. with branded equivalents), the extent of clinical data available for biosimilars, indication extrapolation and naming conventions will all feature prominently as more products reach the market – see ViewPoints: Money for nothing? – Indication extrapolation remains key issue for biosimilar developers and Physician Views: At least some similarity needed in biosimilar naming conventions, say majority of physicians, but caveats remain

In a bid to address these questions and concerns, industry will play a pivotal role in supporting the education of physicians around biosimilars. In turn – among other considerations – it will have to pinpoint where and how best to promote the biosimilar message and in way that is designed to address the needs of patients and physicians, rather than those companies operating in this market segment.

Reasons to purchase this study

Our latest Physician Views poll asks 5 simple questions to oncologists and rheumatologists (the most likely users of biosimilar antibodies) based in the US and EU5:

- How familiar they are with the general concept of biosimilars

- Which issue is causing them the most uncertainty in relation to the current/future use of biosimilars in day-to-day clinical practice (indication extrapolation, substitution, clinical trial design, pro-biosimilar payer policies, naming conventions, patient awareness)

- Where they obtain the majority of their information and knowledge about biosimilars (conferences, printed media, online media, pharma companies, CME providers, other physicians)

- How they rate the quality of current biosimilar medical education programmes

- How they rate the neutrality of current biosimilar medical education programmes

Table Of Contents

Physician Views - Are physicians getting the biosimilar education they need?

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Amrita

+1 718 303 2019

Purchase Reports From Reputable Market Research Publishers
Biosimilars Market by Product, Manufacturing, Application - Global Forecast to 2021

Biosimilars Market by Product, Manufacturing, Application - Global Forecast to 2021

  • $ 5650
  • Industry report
  • January 2017
  • by MarketsandMarkets

Biosimilars Market by Product (Recombinant Non-glycosylated Proteins (Insulin, rHGH, Interferon), glycosylated (mAb, EPO), Peptides (Glucagon, Calcitonin)), Manufacturing (In-House, CM0) & Application ...

Insulin Biosimilars - Global Market Outlook (2016-2022)

Insulin Biosimilars - Global Market Outlook (2016-2022)

  • $ 4157
  • Industry report
  • October 2016
  • by Stratistics MRC

According to Stratistics MRC, the Global Insulin Biosimilars market is accounted for $xx million in 2015 and is expected to reach $xx million by 2022 growing at a CAGR of xx% from 2015 to 2022. Growing ...

Global Biosimilar Drug Market Research Report 2016

Global Biosimilar Drug Market Research Report 2016

  • $ 2850
  • Industry report
  • November 2016
  • by 9Dimen Research

2016 Global Biosimilar Drug Industry Report is a professional and in-depth research report on the world's major regional market conditions of the Biosimilar Drug industry, focusing on the main regions ...


ref:plp2014

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.